Xilio Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Xilio Therapeutics, Inc. filed this Current Report on October 26, 2021, in connection with the closing of its initial public offering of common stock. The filing concerns amendments to the company’s governing corporate documents and does not report operating results for a financial reporting period.
Financial and other key metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, share issuance amounts, or other financial performance metrics.
Material changes
- The company filed a restated certificate of incorporation with the Delaware Secretary of State, effective upon the IPO closing.
- The restated certificate authorizes 200,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.
- All references to the company’s previously existing preferred stock were eliminated.
- The certificate establishes a classified, three-class board with staggered three-year terms.
- Directors may be removed only for cause and only with the affirmative vote of at least 75% of the voting power entitled to elect directors.
- Board vacancies may be filled only by a majority of the directors then in office.
- Stockholders may no longer act by written consent in lieu of a meeting or call special stockholder meetings.
- Amended and restated bylaws became effective upon the IPO closing and establish procedures for stockholder proposals and director nominations, while conforming the bylaws to the restated certificate.
Guidance, risks, contingencies, and unusual items
No financial guidance, operating outlook, management forecast, contingent liability, or clinical update is provided.
The amended governance provisions may limit stockholder ability to take action outside of meetings, remove directors, fill board vacancies, or initiate certain proceedings in alternative forums. The documents designate Delaware state courts, or the federal District of Delaware when applicable, as exclusive forums for specified corporate-law and internal-affairs claims, and federal district courts as the exclusive forum for Securities Act claims, subject to stated exceptions and legal limitations.
Investor verification checklist
- Verify the IPO closing details and related capitalization in the applicable IPO registration statement and subsequent filings.
- Review Exhibit 3.1 for the precise terms of the restated certificate, including preferred-stock authorization, board classification, voting thresholds, and forum-selection provisions.
- Review Exhibit 3.2 for the complete amended and restated bylaws and stockholder meeting, proposal, and nomination procedures.
- Consult subsequent filings for actual post-IPO cash, liquidity, share count, operating results, and financing plans, none of which are reported in this Form 8-K.